EFFICACY OF INTRADERMAL MICRO INJECTION OF TRANEXAMIC ACID VS ORAL TRANEXAMIC ACID FOR THE TREATMENT OF MELASMA

K BIBI; S SALEEM

doi:10.54112/pjicm.v5i02.150

Authors

K BIBI Department of Dermatology, CMH Nowshera, Pakistan
S SALEEM Department of Dermatology, CMH Nowshera, Pakistan

DOI:

https://doi.org/10.54112/pjicm.v5i02.150

Keywords:

Tranexamic Acid, Melasma, Intradermal Injection, Oral Administration, Mmasi Score

Abstract

Background: Melasma is a common acquired hyperpigmentation disorder that significantly affects quality of life. Tranexamic acid (TXA) has recently emerged as a promising therapeutic option, administered via different routes including oral and intradermal delivery. However, comparative evidence regarding their relative efficacy remains limited. Objective: To compare the efficacy of intradermal microinjection of tranexamic acid with oral tranexamic acid in the treatment of melasma. Study Design: A randomized controlled trial. Setting: Department of Dermatology, Combined Military Hospital, Nowshera, Pakistan. Duration of Study: 11-October-2024 to 11-April-2025. Methods: A total of 62 patients with clinically diagnosed melasma were enrolled and allocated equally into two groups. Group A received intradermal TXA microinjections at three-week intervals for five sessions, while Group B received oral TXA 250 mg twice daily for 12 weeks. The primary outcome was the proportion of patients achieving treatment efficacy, assessed by [insert scale used, e.g., MASI reduction if available]. Statistical analysis was performed using the Chi-square test, with a p-value of ≤ 0.05 considered statistically significant. Results: The mean age in Group A was 31.61 ± 11.37 years and in Group B 31.48 ± 10.94 years. A significantly higher proportion of patients in the intradermal TXA group achieved efficacy (64.5%, n = 20) compared with the oral TXA group (29.0%, n = 9) (p = 0.005). Conclusion: Intradermal tranexamic acid microinjections demonstrated significantly superior efficacy compared to oral tranexamic acid in the treatment of melasma. These findings suggest that intradermal administration may be the preferred therapeutic option for achieving optimal clinical outcomes.

References

Doolan BJ, Gupta M. Melasma. Aust J Gen Pract. 2021;50(12):880–5. https://doi.org/10.31128/AJGP-05-21-6002

Liu W, Chen Q, Xia Y. New mechanistic insights of melasma. Clin Cosmet Investig Dermatol. 2023;16:429–42. https://doi.org/10.2147/CCID.S396272

Guinot C, Cheffai S, Latreille J, Dhaoui MA, Youssef S, Jaber K, et al. Aggravating factors for melasma: a prospective study in 197 Tunisian patients. J Eur Acad Dermatol Venereol. 2010;24(9):1060–9. https://doi.org/10.1111/j.1468-3083.2010.03592.x

Tamega AD, Miot LDB, Bonfietti C, Gige TC, Marques MEA, Miot HA. Clinical patterns and epidemiological characteristics of facial melasma in Brazilian women. J Eur Acad Dermatol Venereol. 2013;27(2):151–6. https://doi.org/10.1111/j.1468-3083.2011.04430.x

Sanchez JL. Mandibular melasma. P R Health Sci J. 2000;19(3):231–4.

Ritter CG, Fiss DV, Borges da Costa JA, de Carvalho RR, Bauermann G, Cestari TF, et al. Extra-facial melasma: clinical, histopathological, and immunohistochemical case-control study. J Eur Acad Dermatol Venereol. 2013;27(9):1088–94. https://doi.org/10.1111/j.1468-3083.2012.04655.x

Mishra SN, Dhurat RS, Deshpande DJ, Nayak CS. Diagnostic utility of dermatoscopy in hydroquinone-induced exogenous ochronosis. Int J Dermatol. 2013;52(4):413–7. https://doi.org/10.1111/j.1365-4632.2011.05305.x

Achar A, Rathi SK. Melasma: a clinico-epidemiological study of 312 cases. Indian J Dermatol. 2011;56(4):380–2. https://doi.org/10.4103/0019-5154.84722

Prudovsky I, Kacer D, Zucco VV, Palmeri M, Falank C, Kramer R, et al. Tranexamic acid: beyond antifibrinolysis. Transfusion. 2022;62:301–12. https://doi.org/10.1111/trf.16976

Colomina MJ, Contreras L, Guilabert P, Koo M, Sabaté A. Clinical use of tranexamic acid: evidence and controversies. Braz J Anesthesiol. 2022;72(6):795–812. https://doi.org/10.1016/j.bjane.2021.08.022

Konisky H, Balazic E, Jaller JA, Khanna U, Kobets K. Tranexamic acid in melasma: A focused review on drug administration routes. J Cosmet Dermatol. 2023;22(4):1197–206. https://doi.org/10.1111/jocd.15589

Kalluri H, Banga AK. Microneedles and transdermal drug delivery. J Drug Deliv Sci Technol. 2009;19(5):303–10. https://doi.org/10.1016/S1773-2247(09)50065-2

Shetty VH, Shetty M. Comparative study of localised intradermal microinjection of tranexamic acid and oral tranexamic acid for the treatment of melasma. Int J Res Dermatol. 2018;4(3):363–7. https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20183159

Khurana VK, Misri RR, Agarwal S, Thole AV, Kumar S, Anand T. A randomized, open-label, comparative study of oral tranexamic acid and tranexamic acid microinjections in patients with melasma. Indian J Dermatol Venereol Leprol. 2019;85(1):39–43. https://doi.org/10.4103/ijdvl.IJDVL_801_16

Komal S, Mashhood AA, Farooq M, Qayyum N. A comparison of the efficacy of intradermal tranexamic acid with topical 20% azelaic acid in the treatment of melasma. Pak Armed Forces Med J. 2021;71(2):494–7. https://doi.org/10.51253/pafmj.v71i2.4528

Maeda K, Tomita Y. Mechanism of the inhibitory effect of tranexamic acid on melanogenesis in cultured human melanocytes in the presence of keratinocyte-conditioned medium. J Health Sci. 2007;53(4):389–96. https://doi.org/10.1248/jhs.53.389

Lee JH, Park JG, Lim SH, Kim JY, Ahn KY, Kim MY, et al. Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: a preliminary clinical trial. Dermatol Surg. 2006;32(5):626–31. https://doi.org/10.1111/j.1524-4725.2006.32133.x

Panchal VS, Patel YS, Dalal YD, Parikh AP, Dalal AD, Rana DA. Efficacy of oral, topical, and intradermal tranexamic acid in patients with melasma – a meta-analysis. Indian Dermatol Online J. 2024;15(1):55–63. https://doi.org/10.4103/idoj.idoj_495_22